Compare Garmin Ltd. (GRMN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Summit Therapeutics Inc — how do they compare? Garmin Ltd. trades at $268.36 (market cap $51.77B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Garmin Ltd. is far larger — about 3.8× Summit Therapeutics Inc's market cap, and Garmin Ltd. pays a 1.56% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Summit Therapeutics Inc for 16 Days on average.
| GRMN | SMMT | |
|---|---|---|
Market Cap | $51.77B | $13.71B |
Volume | 961,398 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $313.16 | $26.38 |
52-Week Low | $187.10 | $12.43 |
Typical Hold Time | 83 Days | 16 Days |
Enterprise Value | $49.28B | $13.04B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.44, down 2.8% on the day, amid a bearish technical signal. The stock has demonstrated strong fundamental performance with revenue growing from $4.9B in 2022 to $7.25B in 2025 and net income reaching $1.66B. Recent earnings beats and consistent dividend payments highlight operational strength, while analyst consensus targets $320.25, suggesting potential upside from current levels.
The outlook remains positive given robust profitability and product innovation, but risks include competitive pressures and market volatility. Institutional ownership trends and a Zacks Strong Buy upgrade reflect confidence, yet the stock faces headwinds from broader economic conditions and execution challenges in maintaining growth momentum.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
